Statements (24)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
antineoplastic agent
|
| gptkbp:administeredBy |
oral
intravenous |
| gptkbp:alternativeName |
antineoplastic agent
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
gptkb:L01CB01
|
| gptkbp:CASNumber |
gptkb:33419-42-0
|
| gptkbp:derivedFrom |
gptkb:podophyllotoxin
|
| gptkbp:discoveredBy |
gptkb:Sandoz
|
| gptkbp:hasMolecularFormula |
C29H32O13
|
| https://www.w3.org/2000/01/rdf-schema#label |
VP-16
|
| gptkbp:mechanismOfAction |
topoisomerase II inhibitor
|
| gptkbp:molecularWeight |
588.56 g/mol
|
| gptkbp:sideEffect |
nausea
vomiting hair loss low blood cell counts |
| gptkbp:usedFor |
leukemia
testicular cancer Small Cell Lung Cancer |
| gptkbp:bfsParent |
gptkb:antineoplastic_agent
gptkb:Etoposide gptkb:Patrol_and_Reconnaissance_Wing_Eleven |
| gptkbp:bfsLayer |
6
|